139 related articles for article (PubMed ID: 15678154)
1. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.
Parker JN; Meleth S; Hughes KB; Gillespie GY; Whitley RJ; Markert JM
Cancer Gene Ther; 2005 Apr; 12(4):359-68. PubMed ID: 15678154
[TBL] [Abstract][Full Text] [Related]
2. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.
Markert JM; Cody JJ; Parker JN; Coleman JM; Price KH; Kern ER; Quenelle DC; Lakeman AD; Schoeb TR; Palmer CA; Cartner SC; Gillespie GY; Whitley RJ
J Virol; 2012 May; 86(9):5304-13. PubMed ID: 22379082
[TBL] [Abstract][Full Text] [Related]
4. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
[TBL] [Abstract][Full Text] [Related]
5. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
7. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
9. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
Toda M; Martuza RL; Rabkin SD
Gene Ther; 2001 Feb; 8(4):332-9. PubMed ID: 11313808
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
11. Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma.
Bauer DF; Pereboeva L; Gillespie GY; Cloud GA; Elzafarany O; Langford C; Markert JM; Lamb LS
J Immunol Res; 2016; 2016():2568125. PubMed ID: 27610392
[TBL] [Abstract][Full Text] [Related]
12. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
[TBL] [Abstract][Full Text] [Related]
13. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.
Guffey MB; Parker JN; Luckett WS; Gillespie GY; Meleth S; Whitley RJ; Markert JM
Cancer Gene Ther; 2007 Jan; 14(1):45-56. PubMed ID: 16990846
[TBL] [Abstract][Full Text] [Related]
14. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
[TBL] [Abstract][Full Text] [Related]
15. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
Ino Y; Saeki Y; Fukuhara H; Todo T
Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
[TBL] [Abstract][Full Text] [Related]
16. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
17. Significantly increased expression of beta-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector.
Zhu J; Kang W; Wolfe JH; Fraser NW
Mol Ther; 2000 Jul; 2(1):82-94. PubMed ID: 10899831
[TBL] [Abstract][Full Text] [Related]
18. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
[TBL] [Abstract][Full Text] [Related]
19. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
Andreansky S; He B; van Cott J; McGhee J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Gene Ther; 1998 Jan; 5(1):121-30. PubMed ID: 9536273
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.
Willis RA; Bowers WJ; Turner MJ; Fisher TL; Abdul-Alim CS; Howard DF; Federoff HJ; Lord EM; Frelinger JG
Hum Gene Ther; 2001 Oct; 12(15):1867-79. PubMed ID: 11589829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
